Abbott buys potential kidney treatment for $110 million

    Abbott Laboratories will spend $110 million to buy a potential kidney treatment from the privately held Danish company Action Pharma, the company said Thursday.

    The drug, labeled AP214, is in mid-stage clinical testing and is designed to prevent acute kidney injury in patients undergoing major cardiac surgery. The molecule targets systemic inflammation and cellular death caused by a lack of blood flow that can occur during surgery.

    North Chicago-based Abbott said the deal will improve its pipeline of renal care drugs under development, which includes two potential chronic kidney disease treatments.

    Read more.

    Sign up for BizTimes Daily Alerts

    Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin

    No posts to display